Background The aim of this study was to quantify the long‐term clinical outcomes for individuals receiving teduglutide for short‐bowel syndrome (SBS). Methods A single‐center, retrospective study was performed for individuals commencing use of teduglutide between March 2013 and May 2019. Results Eighteen patients were included in the final analysis, among which the median duration of teduglutide administration was 3.2 (range, 0.6–6.2) years. Twelve of 16 (75%) patients at 12 months, 10 of 13 (76.9%) at 24 months, 7 of 10 (70%) at 36 months, and 3 of 3 (100%) at 60 months had a response to teduglutide therapy, defined as a >20% reduction in parenteral support (PS) requirement. Among responders at 12, 24, and 36 months, the presence of a colon‐in‐continuity, an ileocecal valve, a response at 3 months, the length of small bowel, nor the baseline volume affected response to therapy (P > .05 for all comparisons). Five (28%) patients were able to achieve freedom from PS, among which all had a history of Crohn's disease with loss of the ileocecal valve and among which 3 had a colon‐in‐continuity. Four of the 5 patients discontinued PS by 6 months of teduglutide therapy. Conclusions In a real‐world experience, teduglutide therapy results in rapid and sustained reductions in PS. Larger postmarketing studies will be required to reliably predict response to treatment and the factors associated with enteral autonomy.

No abstract

No abstract

MDK was an investigator and grant holder as part of the Prenatal Assessment of Genomes and Exomes (PAGE) study. This represents research commissioned by the Health Innovation Challenge Fund (HICF-R7-396), a parallel funding partnership between the Department of Health and the Wellcome Trust. The views expressed in this publication are those of the author and not necessarily those of the Department of Health or the Wellcome Trust. MDK is also a member of the RCOG Genomics Taskforce, the RCOG representative of the Joint Committee on Genomics in Medicine (joint committee of the Royal College of Physicians, Royal College of Pathologists, Royal College of Paediatricians & Child Health, Royal of Obstetricians and Gynaecologists) and a member of the Fetal Group of the British Society of Genetic Medicine. Funding: No external funding provided for this review. Author contributions: JSC and EW researched and wrote the article, contributing equally as joint first authors*. DW, SD and MDK instigated, reviewed and edited the article. SKA reviewed and edited the article. All authors approved the final version.

No abstract